Hemostasis News and Research

RSS

Hemostasis or haemostasis is a complex process which causes the bleeding process to stop. Most times this includes the changing of blood from a fluid to a solid state. Intact blood vessels are central to moderating blood's tendency to clot.

Members of JUGGLE network collaborate to improve project coordination

The field of life sciences is at the crossroads of biology and medicine and is a key component of the research portfolio of Johannes Gutenberg University Mainz (JGU).

28 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Cook Medical's Instinct Endoscopic Hemoclip now available to gastroenterologists

The Instinct Endoscopic Hemoclip is now available to gastroenterologists in major global markets. The clip is used to stop gastrointestinal (GI) tract bleeding, which is a condition that can be challenging to treat because of the variations among bleeds.

From COOK MEDICAL INC. 23 Apr 2014

Researcher develops synthetic hydrogel that promotes natural clotting, heals surgical wounds

Synthetic collagen invented at Rice University may help wounds heal by directing the natural clotting of blood.

10 Apr 2014

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration.

2 Apr 2014

Scientists discover how MRP-14 gene generates dangerous clots that could trigger heart attack

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

2 Apr 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

AccessClosure commercially launches Mynx Ace Vascular Closure Device

AccessClosure Inc., the market leader in extravascular care technology, has commercially launched its Mynx Ace Vascular Closure Device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites.

29 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

LFB SA initiates Phase 3 program for human Factor VIIa in patients with congenital hemophilia

LFB SA, through its rEVO Biologics subsidiary, announced today initiation of the global Phase 3 program for LR769, a novel recombinant form of human Factor VIIa, in patients with congenital hemophilia A or B with inhibitors.

4 Mar 2014

New hemostasis valve with sideport tubing and stopcock launched by Qosina

...

11 Feb 2014

T2HemoStat detection of novel clot behavior could direct therapeutic choices for stroke, heart attack victims

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat-.

10 Jan 2014

Qosina announces addition of new Control Stroke Syringes

Qosina is pleased to announce the addition of five new Control Stroke Syringes. These syringes help ensure volume regulation during fluid delivery, and are used for precise injection or withdrawal. All syringes are equipped with a dimple inside the barrel opposite the graduation, which acts as a plunger stop.

8 Jan 2014

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

Alnylam presents new pre-clinical data with ALN-AT3 for treatment of hemophilia and RBD

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), at the 55th Annual Meeting of the American Society of Hematology (ASH) held December 7 - 10, 2013 in New Orleans.

10 Dec 2013

New Torquers announced by Qosina

Qosina is pleased to announce the addition of three new Torquers, #97344 for use with guide wires 0.008 inch - 0.018 inch (0.20 mm - 0.46 mm, 0.6 FR - 1.4 FR) and #97345 or #97346 which fit 0.014 inch - 0.038 inch (0.36 mm - 0.96 mm, 1.1 FR - 3 FR). Torquer #97346 has a narrow profile design which is smaller and lighter than the other two.

8 Nov 2013

Haemonetics net revenue increases 8% to $235.8 million in Q2 fiscal 2014

Haemonetics Corporation today reported second quarter fiscal 2014 net revenue of $235.8 million, up 8%, GAAP net income of $16.5 million and earnings per share of $0.32. Adjusted net income, exclusive of transformation, integration and deal amortization expenses detailed below, was $34.4 million, up 24%, and adjusted earnings per share were $0.66, up 24%. Excluding currency impact, net revenue was up 11% in the quarter.

28 Oct 2013

Understanding the biological players in clot formation could lead to new thrombotic therapies

Ulhas Naik, professor of biological sciences and director of the Delaware Cardiovascular Research Center, pores over laboratory data on his computer, even during breakfast most mornings. He is on a quest to tease out the roles that various blood components play in the formation of clots.

9 Oct 2013

Polycarbonate non-luer connectors now available from Qosina

Qosina now stocks SMC series polycarbonate non-luer connectors from Colder Products CompanyÒ. The SMC is a twist-to-connect coupling that provides a reliable and more secure alternative to traditional luer-type connections and will not mate to a standard luer.

4 Oct 2013